US patent secured for PromarkerEso diagnostic test for EAC
Filed with ASX · · 2 pages · English
• Major milestone as the patent underpins the commercialisation pathway in the world's largest healthcare market, enabling direct sales, future partnerships and licensing opportunities • Patents for the PromarkerEso diagnostic test now cover multiple jurisdictions including Australia, China, Hong Kong, Europe and the USA • Global health impact: currently 90% of EAC cases go undetected until late s
Proteomics International Laboratories Ltd. on 6ix
In the deck
Story so far
Earlier from Proteomics International Laboratories
- PromarkerD predicts risk of DKD in Aboriginal Australians
- Response to ASX Price Query
- US Medicare sets reimbursement price for PromarkerD DKD test
- OxiDx test correlates with superior racehorse performance
- Proteomics International receives $2.2m in R&D tax incentive
Later from Proteomics International Laboratories
- Proteomics US lab CAP accredited - extends precision Dx lab
- Appointment of CEO and Managing Director
- Canadian patent secured for PromarkerEso test for EAC
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4D and Interim Financial Report
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories